Propel Bio Management, LLC
Filing Date
Global Rank
#4,396
/ 8,603
▲ 1128
· as of Mar 2026
Top Industry
Biotechnology
74.2%
3Y Alpha vs SPY
-0.1%
Period ended 3 months ago
Filed May 14, 2026 · 56d
10 quarters · since Dec 2023
Clone Performance
Feb 2024–Jul 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+58.6%
SPY
+54.1%
Annualised alpha
+1.4%
Max drawdown
−40.4%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
38 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
17.0%
−3.8 pts
Top 5
47.5%
−14.5 pts
Top 10
62.9%
−21.0 pts
HHI
689
Diversified−356
Portfolio Trend
10 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 83.0% | $151,211,923 |
| Energy | 17.0% | $30,892,900 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
6 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| DCTH | Delcath Systems, Inc. | +541,189 | 979,698 | $9,091,597 | |
| ABEO | Abeona Therapeutics Inc. | +499,119 | 1,329,899 | $5,957,947 | |
| SABS | SAB Biotherapeutics, Inc. | +359,909 | 1,012,790 | $3,878,985 | |
| KLRS | Kalaris Therapeutics, Inc. | +253,718 | 295,771 | $1,706,598 | |
| ZVRA | Zevra Therapeutics, Inc. | +218,735 | 282,418 | $2,632,135 | |
| PHAT | Phathom Pharmaceuticals, Inc. | +100,354 | 841,272 | $9,346,531 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
6 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IVA | Inventiva S.A. | −275,322 | 724,678 | $4,021,962 | |
| CMPS | COMPASS Pathways plc | −119,729 | 742,049 | $4,103,530 | |
| VRDN | Viridian Therapeutics, Inc.\DE | −72,368 | 210,163 | $4,110,788 | |
| OCS | Oculis Holding AG | −50,616 | 122,223 | $3,249,909 | |
| CLDX | Celldex Therapeutics, Inc. | −22,936 | 131,364 | $4,166,866 | |
| KYTX | Kyverna Therapeutics, Inc. | −22,245 | 644,421 | $5,561,353 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
22 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| IMUX | Immunic, Inc. | 2,344,779 | $26,027,046 | |
| CORT | Corcept Therapeutics Inc | 147,828 | $5,958,946 | |
| VOR | Vor Biopharma Inc. | 314,543 | $5,611,447 | |
| OBIO | Orchestra BioMed Holdings, Inc. | 896,701 | $3,810,979 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 380,420 | $3,541,710 | |
| OCUL | Ocular Therapeutix, Inc | 382,375 | $3,238,716 | |
| UPB | Upstream Bio, Inc. | 341,779 | $3,076,011 | |
| AQST | Aquestive Therapeutics, Inc. | 710,988 | $2,950,600 | |
| EYPT | EyePoint, Inc. | 215,825 | $2,781,984 | |
| TRVI | Trevi Therapeutics, Inc. | 223,802 | $2,669,957 | |
| CHRS | Coherus Oncology, Inc. | 1,420,550 | $2,400,729 | |
| OVID | Ovid Therapeutics Inc. | 921,457 | $2,045,634 | |
| PALI | Palisade Bio, Inc. | 1,115,000 | $1,951,250 | |
| QURE | uniQure N.V. | 104,772 | $1,713,022 | |
| NUVB | Nuvation Bio Inc. | 329,296 | $1,412,679 | |
| MAZE | Maze Therapeutics, Inc. | 43,798 | $1,307,370 | |
| EVMN | Evommune, Inc. | 55,664 | $1,279,715 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 85,791 | $1,255,122 | |
| ALDX | Aldeyra Therapeutics, Inc. | 730,606 | $1,234,724 | |
| ARTV | Artiva Biotherapeutics, Inc. | 146,369 | $942,616 | |
| CNTB | Connect Biopharma Holdings Ltd | 209,493 | $548,871 | |
| MSLE | Satellos Bioscience Inc. | 10,145 | $57,116 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
4 positions
38 positions ·
$182,104,823 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| PAGP |
Plains Gp Holdings LP
Energy
|
Held | 1,272,360 | $30,892,900 | 16.96% | |
| IMUX |
Immunic, Inc.
Healthcare
|
NEW | 2,344,779 | $26,027,046 | 14.29% | |
| ACHV |
Achieve Life Sciences, Inc.
Healthcare
|
Held | 3,786,425 | $11,132,089 | 6.11% | |
| PHAT |
Phathom Pharmaceuticals, Inc.
Healthcare
|
Added | 841,272 | $9,346,531 | 5.13% | |
| DCTH |
Delcath Systems, Inc.
Healthcare
|
Added | 979,698 | $9,091,597 | 4.99% | |
| CORT |
Corcept Therapeutics Inc
Healthcare
|
NEW | 147,828 | $5,958,946 | 3.27% | |
| ABEO |
Abeona Therapeutics Inc.
Healthcare
|
Added | 1,329,899 | $5,957,947 | 3.27% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
NEW | 314,543 | $5,611,447 | 3.08% | |
| KYTX |
Kyverna Therapeutics, Inc.
Healthcare
|
Reduced | 644,421 | $5,561,353 | 3.05% | |
| MIST |
Milestone Pharmaceuticals Inc.
Healthcare
|
Held | 4,118,321 | $4,900,801 | 2.69% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Reduced | 131,364 | $4,166,866 | 2.29% | |
| VRDN |
Viridian Therapeutics, Inc.\DE
Healthcare
|
Reduced | 210,163 | $4,110,788 | 2.26% | |
| CMPS |
COMPASS Pathways plc
Healthcare
|
Reduced | 742,049 | $4,103,530 | 2.25% | |
| IVA |
Inventiva S.A.
Healthcare
|
Reduced | 724,678 | $4,021,962 | 2.21% | |
| SABS |
SAB Biotherapeutics, Inc.
Healthcare
|
Added | 1,012,790 | $3,878,985 | 2.13% | |
| OBIO |
Orchestra BioMed Holdings, Inc.
Healthcare
|
NEW | 896,701 | $3,810,979 | 2.09% | |
| FDMT |
4D Molecular Therapeutics, Inc.
Healthcare
|
NEW | 380,420 | $3,541,710 | 1.94% | |
| OCS |
Oculis Holding AG
Healthcare
|
Reduced | 122,223 | $3,249,909 | 1.78% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
NEW | 382,375 | $3,238,716 | 1.78% | |
| UPB |
Upstream Bio, Inc.
Healthcare
|
NEW | 341,779 | $3,076,011 | 1.69% | |
| AQST |
Aquestive Therapeutics, Inc.
Healthcare
|
NEW | 710,988 | $2,950,600 | 1.62% | |
| EYPT |
EyePoint, Inc.
Healthcare
|
NEW | 215,825 | $2,781,984 | 1.53% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
NEW | 223,802 | $2,669,957 | 1.47% | |
| ZVRA |
Zevra Therapeutics, Inc.
Healthcare
|
Added | 282,418 | $2,632,135 | 1.45% | |
| CHRS |
Coherus Oncology, Inc.
Healthcare
|
NEW | 1,420,550 | $2,400,729 | 1.32% | |
| OVID |
Ovid Therapeutics Inc.
Healthcare
|
NEW | 921,457 | $2,045,634 | 1.12% | |
| PALI |
Palisade Bio, Inc.
Healthcare
|
NEW | 1,115,000 | $1,951,250 | 1.07% | |
| QURE |
uniQure N.V.
Healthcare
|
NEW | 104,772 | $1,713,022 | 0.94% | |
| KLRS |
Kalaris Therapeutics, Inc.
Healthcare
|
Added | 295,771 | $1,706,598 | 0.94% | |
| LONA |
LeonaBio, Inc.
Healthcare
|
Held | 149,279 | $1,534,588 | 0.84% | |
| NUVB |
Nuvation Bio Inc.
Healthcare
|
NEW | 329,296 | $1,412,679 | 0.78% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
NEW | 43,798 | $1,307,370 | 0.72% | |
| EVMN |
Evommune, Inc.
Healthcare
|
NEW | 55,664 | $1,279,715 | 0.70% | |
| CRVS |
Corvus Pharmaceuticals, Inc.
Healthcare
|
NEW | 85,791 | $1,255,122 | 0.69% | |
| ALDX |
Aldeyra Therapeutics, Inc.
Healthcare
|
NEW | 730,606 | $1,234,724 | 0.68% | |
| ARTV |
Artiva Biotherapeutics, Inc.
Healthcare
|
NEW | 146,369 | $942,616 | 0.52% | |
| CNTB |
Connect Biopharma Holdings Ltd
Healthcare
|
NEW | 209,493 | $548,871 | 0.30% | |
| MSLE |
Satellos Bioscience Inc.
Healthcare
|
NEW | 10,145 | $57,116 | 0.03% |